The Blind Spot in Bladder Cancer Care: What Patients Don’t Say

Not long ago, I saw a patient whose disease was, by all clinical measures, under control.

Her cystoscopy was clear. She was completing therapy as planned. There were no complications that would raise concern.

At the end of the visit, I asked how she was doing. She said, “I’m fine.”

It wasn’t until we were wrapping up that she added, almost as an afterthought, that she had stopped going out to dinner with her friends as often as she used to — the unpredictability of her voiding symptoms made it too stressful. She didn’t want to explain them to anyone, so she simply stayed home.

Nothing about that would have shown up in her chart. And it wasn’t something she planned to bring up.

Experiences like this are easy to miss in bladder cancer care, even when the clinical picture looks reassuring.

If Patients Feel Comfortable Speaking Up, Why Aren’t They?

On the surface, communication between patients and urologists appears strong.

A recent global survey from more than 800 patients with non-muscle-invasive bladder cancer (NMIBC) and more than 800 urologists across six countries found that nearly nine in 10 patients report feeling comfortable having open and honest conversations with their urologist. The survey was conducted by the Harris Poll in collaboration with several patient advocacy and bladder cancer organizations.

But the same data reveal a more complicated reality.

Three in four patients say they hide the emotional impact of their disease from their urologist, and one in three say they do so always or often. At the same time, a large majority of urologists believe their patients are comfortable discussing these issues.

Comfort, it turns out, is not the same as disclosure.

Patients may trust their physicians and still struggle to articulate what they are experiencing. Clinic visits are often centered on procedures, surveillance, and next steps. Emotional burden is harder to quantify and easier to leave unspoken.

What Patients Experience Between Visits

For many patients, the burden of treatment extends well beyond our clinics.

Patients describe withdrawing from social activities and adjusting their routines around the realities of ongoing care. In the same survey, nearly all (94%) report missing one or more listed life moments due to treatment, and more than one in three avoid socializing with friends and family or going out in public altogether.

Among patients treated with bacillus Calmette-Guérin, one of the most common therapies for NMIBC, many describe a loss of control over their body, loss of dignity or sense of self, and treatment-related symptoms they found humiliating.

Meanwhile, nearly nine in 10 patients say they wish they had been better prepared for the mental and emotional impact of treatment — while most urologists believe they are already providing that preparation. And 77% of patients reported they were not prepared for the mental and emotional toll of the disease.

As urologists, we aim to reduce fear. But if reassurance comes at the expense of preparation, patients may find themselves unready for the reality of living with a chronic, recurring condition that requires ongoing treatment and surveillance.

Why This Matters for Decision-Making

Trust between patients and urologists is strong — and that trust is foundational to care. But trust does not always mean alignment.

In routine practice, treatment discussions often focus on disease control and surveillance. But many patients leave those conversations feeling unprepared for how treatment may affect their daily lives. That disconnect matters because treatment decisions are not based on disease control alone. They are shaped by how patients experience life between visits.

That may help explain why many patients feel unprepared for what comes next.

These findings suggest a consistent disconnect: even when communication appears strong, patients and urologists are not always operating with the same understanding of what the treatment experience will be.

This is the blind spot in bladder cancer care: not a lack of trust but the reality that important parts of the patient experience often remain unspoken. For urologists, treatment decisions require balancing multiple factors: achieving disease control while also recognizing the broader impact treatment may have on patients’ lives.

When parts of the patient experience remain unspoken, that balance becomes harder to achieve.

What Would More Complete Care Look Like?

Bladder cancer care has advanced significantly. Our understanding of the patient experience must advance with it.

That includes making space for conversations about emotional and day-to-day impacts, not as an afterthought, but as part of routine care.

It also means being more deliberate in how we set expectations. Patients may not expect certainty, but they do benefit from a clearer picture of how treatment may affect their daily lives — both immediately and over time. And it means continuing to push for treatment approaches that not only control disease, but also reduce burden and preserve quality of life, goals that both patients and urologists increasingly recognize as essential.

As physicians, we are trained to focus on what we can measure. But recurrence rates and cystoscopy findings do not capture the full burden of bladder cancer. The most important part of a patient’s experience is often the part that never makes it into the chart.